This study, called DETECT II, is testing two ways to treat Fuchs endothelial dystrophy (a condition where cells in the eye's cornea don't work well). It compares a standard surgery (DMEK) with a different surgery (Descemet Stripping Only, or DSO) combined with an eye drop called Ripasudil. Researchers want to see if these treatments improve your vision, measured by how well you can see with glasses or contacts after 12 months. You might be able to join if you are over 18, have Fuchs dystrophy, and meet specific criteria for your eye health. This study is currently unclear on its status and plans to enroll 60 patients.

Study design

This is a multi-center, placebo-controlled study that will randomly assign 60 patients with Fuchs endothelial dystrophy to different treatments. It is designed so that the people measuring the results won't know which treatment you received.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your vision will be measured at 12 months after treatment to see how well the treatments worked.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.